allergic rhinoconjunctivitis
Conditions
Interventions
SLIT Group:Artemisia annua SLIT combined with symptomatic medication
Control Group:Only received symptomatic medication
Sponsors
Ordos Central Hospital
Eligibility
Sex/Gender
All
Age
4 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Aged of 4-60 years old (including 4 and 60 years old), with no gender limitations. (2) Diagnosed with moderate to severe allergic rhinitis with allergic conjunctivitis. (3) The patients' serum-specific IgE test is positive (sIgE = 0.7 kU/L), or Artemisia annua SPT is positive with skin prick test at least "++". (4) The patients are able to understand and sign the informed consent file. (5) The patients are able to comply with the treatment plan.
Exclusion criteria
Exclusion criteria: (1) Patients with a history of severe systemic allergic reactions and eosinophilic esophagitis prior to screening and evaluation. (2) Perennial allergic rhinitis. (3) Patients diagnosed with moderate or severe asthma within 2 years before enrollment or evidence of FEV1 < 70% of the predicted value. (4) Patients receiving treatment with ß-blockers (systemic or topical) or angiotensin-converting enzyme (ACE) inhibitors. (5) Patients with a history of immunosuppressive diseases (such as HIV infection), malignant tumors, autoimmune diseases, tuberculosis, cardiovascular insufficiency, or other serious illnesses as determined by researchers. (6) Any other conditions deemed unsuitable for trial participation were assessed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| combined symptom and medication score for rhinoconjunctivitis; | — |
Secondary
| Measure | Time frame |
|---|---|
| total rhinoconjunctivitis symptom score;total medication score; | — |
Countries
China
Contacts
Public ContactJin Li
Ordos Central Hospital
Outcome results
None listed